Ken Griffin’s Citadel Investment Boosts Its Stake in Beazer Homes USA Inc. (BZH)

In its latest 13G, Citadel Investment Group, managed by Ken Griffin, has reported raising its stake in Beazer Homes USA Inc. (NYSE:BZH) to 1.34 million common stock shares. The passive stake amasses 5.3% of the stock, and has been upped from around 201,000 shares held earlier by the fund.

Beazer Homes USA, Inc. (NYSE:BZH)

Beazer Homes USA Inc. (NYSE:BZH), which has been building homes across the United states for more than 35 years, reported first quarter fiscal 2014 results on January 30. According to the company, highlights for the quarter included a 310 basis point improvement in homebuilding gross margins, an 18.6% increase in average sales prices and adjusted EBITDA of $21.6 million, nearly triple the amount recorded a year ago.

At the end of the third quarter of 2013, David Tepper’s Appaloosa Management LP held 1.21 million shares of Beazer Homes USA Inc. (NYSE:BZH). Alden Global Capital, managed by Randall Smith, owned 1.0 million shares, with a reported value of around $18.0 million.

Citadel Investment Group, in another filing, has disclosed a new stake in New Home Company Inc (NYSE:NWHM). The stake contains 917,136 shares, equal to 5.2% of the common stock. In a separate filing, the fund also revealed that it has significantly upped its stake in Ralph Lauren Corp (NYSE:RL) to 3.17 million shares, from 1.16 million shares held at the end of the third quarter. The current holding equals to 5.3% of the common stock of the company.

Disclosure: none

Recommended reading:

Roumell Asset Management Dumps Tecumseh Products Company (TECUA)

Joel Ramin’s 12 West Capital Discloses New Passive Stake in Zulily Inc (ZU)

Charles Paquelet’s Skylands Capital Is Bullish On These Stocks

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!